|
|
||||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
1 Hunter Area Pathology Service, Locked Bag 1, HRMC, Newcastle, Australia 2310
2 Hunter Area Pathology Service, Newcastle, Australia
3 Cancer Research Unit, University of Newcastle, Australia
4 Hunter Area Pathology Service
Correspondence to:
Professor A S-Y Leong
Hunter Area Pathology Service, Locked Bag 1, HRMC, Newcastle, Australia 2310; aleong{at}mail.newcastle.edu.au
Aim: To identify surrogate prognostic markers in intrahepatic cholangiocarcinoma (IHCC).
Methods: Thirty one cases of IHCC were graded and immunostained for FAT, Ki67, E-cadherin, ß catenin, and HER 2/neu.
Results: Twenty two cases were high grade and 27 had high Ki67 counts. Strong membranous staining of HER 2/neu was found in 10 tumours and reduced membranous E-cadherin and ß catenin in 19 and 18 tumours, respectively. Nuclear localisation of ß catenin was identified in five tumours and 22 showed weak cytoplasmic staining of FAT. Strong HER 2/neu and weak FAT immunoexpression were significantly correlated with high histological grade (p = 0.01) and high Ki67 index (p = 0.03). Upregulation of HER 2/neu was also significantly associated with nuclear localisation of ß catenin (p = 0.01). Reduced membranous ß catenin was significantly related to reduced membranous E-cadherin (p = 0.03), weak staining for FAT (p = 0.01), and nuclear translocation of ß catenin (p = 0.04).
Conclusions: Reduced immunoexpression of E-cadherin and FAT at their normal membranous location may be potential prognostic markers, and the overexpression of HER 2/neu and ß catenin nuclear translocation may have a role in cholangiocarcinogenesis.
Abbreviations: IHCC, intrahepatic cholangiocarcinoma
Keywords: Ki67 index; histological grade; HER 2/neu; E-cadherin; ßcatenin; FAT; prognosis; immunohistochemistry
This article has been cited by other articles:
![]() |
K. Lim, C. Han, L. Xu, K. Isse, A. J. Demetris, and T. Wu Cyclooxygenase-2 Derived Prostaglandin E2 Activates -Catenin in Human Cholangiocarcinoma Cells: Evidence for Inhibition of These Signaling Pathways by {omega}3 Polyunsaturated Fatty Acids Cancer Res., January 15, 2008; 68(2): 553 - 560. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |